Involving personnel with close association to Cornell - co-investigator on project - research in the Zhou lab focuses on dissecting the physiological and pathological functions of ubiquitin-dependent proteolysis, and developing chemical inhibitors of Cullin-based ubiquitin ligases as novel therapeutic agents. With the extensive interrogation of kinases and G protein-coupled receptors, ubiquitin ligases are now considered as the next frontier for drug discovery. The Zhou laboratory employs a combination of chemical biology, biochemistry, cell and molecular biology, mouse genetics, and human pathobiology approaches to interrogate the ubiquitin ligases as potential targets for therapeutic intervention.
